Literature DB >> 90740

Long-term antithyroid treatment in hyperthyroidism.

D W Slingerland, B A Burrows.   

Abstract

The major drawback to treatment of hyperthyroidism with antithyroid compounds is the reported low rate of remission. Eighty patients have been given long-term (at least one year; average, 4.4 years; range, one to 14 years) continuous treatment with a remission rate of 76% and an average follow-up of 7.8 years (one to 21 years). The prognostic test of suppressed uptake by the thyroid of less than 20% was about 75% accurate in predicting continuing remission when treatment was stopped. Of those in remission, 14 (23%) were treated for one year, 35 (57%) for one to five years, and 12 (20%) for more than five years. Mild reactions occurred in five (6%), hypothyroidism in two (3%). An antithyroid drug is safe and effective therapy for hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 90740

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

1.  Safety of long-term antithyroid drug treatment? A systematic review.

Authors:  F Azizi; R Malboosbaf
Journal:  J Endocrinol Invest       Date:  2019-05-27       Impact factor: 4.256

2.  Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008.

Authors:  Ana B Emiliano; Laura Governale; Mary Parks; David S Cooper
Journal:  J Clin Endocrinol Metab       Date:  2010-03-24       Impact factor: 5.958

3.  Are antithyroid drugs immunosuppressive?

Authors:  P Kendall-Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

4.  Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.

Authors:  G Edan; C Massart; B Hody; J Y Poirier; M Lé Reun; J P Hespel; G Leclech; M Simon
Journal:  BMJ       Date:  1989-02-11

Review 5.  Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review.

Authors:  F Azizi; H Abdi; L Mehran; A Amouzegar
Journal:  J Endocrinol Invest       Date:  2022-01-28       Impact factor: 4.256

6.  [Surgical therapeutic concept of immune thyropathy].

Authors:  H Dralle; O Schober; R D Hesch
Journal:  Langenbecks Arch Chir       Date:  1987

7.  Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

Authors:  R V García-Mayor; C Páramo; R Luna Cano; L F Pérez Mendez; J C Galofré; A Andrade
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

Review 8.  Clinical pharmacokinetics of antithyroid drugs.

Authors:  J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

9.  A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice.

Authors:  Xiaomei Liu; Wei Qiang; Xingjun Liu; Lianye Liu; Shu Liu; Aibo Gao; Shan Gao; Bingyin Shi
Journal:  Eur J Endocrinol       Date:  2014-12-02       Impact factor: 6.664

10.  Efficacy of low-dose methimazole in control of multiple relapses of Graves' hyperthyroidism: a case report.

Authors:  Fereidoun Azizi; Atieh Amouzegar; Hengameh Abdi
Journal:  J Med Case Rep       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.